President and CEO of InterVivo Solutions, a specialized CRO focused on optimizing translational services to facilitate the development of CNS drugs.
More than 35 refereed publications and several invited presentations, which focus on natural aged canine models of human disease.
Has co-founded, held executive positions and consulted for Life Science companies including CanCog Technologies, Vivocore, Karyopharm Therapeutics, NPM Pharma and Ketogen.
Has conducted extensive research examining psychoactive drugs.
Senior VP of Innovation
Founder, President & Chief Scientific Officer of Fluorinov Pharma Inc. acquired by Trillium Therapeutics in January 2016.
30 + years of experience in successful identification & development of small molecule drug candidates across multiple therapeutic areas, including CNS.
Former Senior Vice President of Discovery Research at Trillium Therapeutics and Vice President of Medicinal Chemistry, Manufacturing & Development at Cascade Therapeutics, and earlier Dr. Slassi held management & scientific positions at Allelix Biopharmaceuticals, Bio-Mega/Boehringer-Ingelheim Research and NPS Pharmaceuticals.
Involved in multinational R&D collaborations with Hoechst AG (Sanofi-Aventis), AstraZeneca, Johnson & Johnson, Forest Laboratories, GlaxoSmithKline, Memory and Shire Pharmaceuticals.
Over 24 drug candidates advanced into late-stage preclinical, clinical development & market; co-authored over 65 research papers and review articles, and he is an inventor of over 130 issued patents & patent applications.
Holds a Ph.D. in chemistry from the University of Claude Bernard, Lyon, France and completed his postdoctoral work in the Chemistry Department at the University of Montreal, Canada.
Professor of Neurology and Pharmacology at the University of California, Davis School of Medicine.
Serves as lead of the University of California Drug Discovery Consortium.
Formerly chief of the Epilepsy Research Section at the National Institute of Neurological Disorders and Stroke.
Member of board of directors of the American Epilepsy Society.
Authored more than 275 research papers, reviews, and book chapters, and edited five books.
Received M.D. and Ph.D. (Pharmacology) from Yale and trained in neurology at Johns Hopkins.
20+ years leading International CNS Research and Development experience with major BioPharma organisations such as Glaxo-Wellcome, Hoffmann-La Roche, Schering Plough and NPS Pharmaceuticals.
Supported the identification and progression of novel chemical entities from early discovery through to clinical development (> 10 entering IND phase, 3 to market).
Significant background in serotonin research both in terms of contributions to drug discovery programs and applied research.
Co-authored over 150 research papers and review articles covering aspects of CNS pharmacology, drug discovery and behavioural neuroscience. Over 70 publications in serotonin based research.
Received PhD in 1990 and currently holds the position of Adjunct Professor in the Pharmacology department at the University of Toronto.
Co-founder of Delivra Corp, a transdermal delivery platform that can shuttle small biologics to large peptides across the skin layers in a targeted, specific manner.
Has received numerous awards throughout his career including a Canadian Institutes of Health Research (CIHR) studentship award in pharmacology, a Natural Sciences andEngineering Research Council of Canada (NSERC) Graduate Scholarship, and an Ontario Mental Health Foundation Postdoctoral Fellowship.
In 2007, he received the International Congress on Schizophrenia Research "New Investigator Award," and in 2008, the Hamilton Health Sciences "New Investigator Award."
In 2018, Dr. Gabriele was the recipient of the Ernst & Young Entrepreneur of the Year in the health care category.
Received his B.Sc degree from the University of Toronto, while his M.Sc. and Ph.D. degrees were received from McMaster University.